COLUMBIA, Md. - TelAve -- Precision Antibody, a leading provider of custom monoclonal antibody development services, is pleased to announce its participation in Antibody Engineering & Therapeutics: Accelerating Tomorrow's Antibody Therapeutics Today, taking place December 14–17, 2025, at the Marriott Marquis San Diego, California.

Hosted by Informa Connect, Antibody Engineering & Therapeutics is one of the most influential global events dedicated to advancing antibody discovery, engineering, and therapeutic development. The conference brings together industry leaders, researchers, and innovators shaping the future of biologics and antibody-based medicines.

Precision Antibody will attend the event to engage with the global antibody community and highlight its expertise in delivering high-quality, application-ready monoclonal antibodies that accelerate drug discovery, biomarker validation, and translational research.

More on TelAve News

• Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
• David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
• "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
• Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
• U.S. Congressional Candidate Peter Coe Verbica on America's Asymmetric Crisis

"This meeting provides an exceptional platform to exchange ideas and collaborate with leaders driving the next generation of antibody therapeutics," said Dr. Serrero. "We look forward to connecting with researchers and partners who share our commitment to scientific rigor and antibody performance."

As biomarker antibody specialists, Precision Antibody has a strong track record of success in developing high-quality biomarker antibodies for oncology and precision medicine applications. The company is also a proud contributor to the National Cancer Institute's (NCI) Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies that are widely used in cancer biomarker research.

Attendees of Antibody Engineering & Therapeutics 2025 are invited to connect with the Precision Antibody team in San Diego to learn how its custom monoclonal antibody development platform supports reliable, reproducible, and high-impact research outcomes.

About Precision Antibody

More on TelAve News

• Jones Sign Rebrands as Jones to Reflect Growth, Innovation, and Expanded Capabilities
• $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
• ELEOLUXE Sets Out a New Framework for Residential Renovation Intelligence
• Trends Journal's Top Trends of 2026
• CollabWait to Launch Innovative Waitlist Management Platform for Behavioral Health Services

Founded in 2000, Precision Antibody is a U.S.-based biotechnology company specializing in the rapid development of custom monoclonal antibodies. Known for delivering antibodies that work "right the first time," the company supports pharmaceutical, biotech, academic, and government researchers worldwide. With a proven track record in biomarker antibody development and contributions to the NCI's Clinical Proteomic Technologies for Cancer (CPTC) program, Precision Antibody is recognized for setting benchmarks in antibody quality and reliability. In 2025, the company was honored as the Best Monoclonal Antibody Development Company, reinforcing its leadership and commitment to advancing diagnostics, therapeutics, and translational research through high-performance, royalty-free antibodies.

Media Contact:
Precision Antibody
Dr. Jun Hayashi
President
Phone: 410-884-4100
Email: info@precisionantibody.com
Website: http://www.precisionantibody.com